Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Merck & Co. agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising ...
Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are ...
Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...
MSD’s acquisition of Terns Pharmaceuticals is a calculated, forward-looking manoeuvre to secure the next generation of ...
If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low ...
Merck , operating as MSD outside the U.S. and Canada, on Wednesday said it will acquire clinical-stage biotech Terns ...
Pharmaceutical company Merck is nearing a roughly $6 billion all-cash deal to acquire biotech firm Terns Pharma , the ...
Merck & Co Inc (NYSE:MRK, XETRA:6MK) announced on Wednesday that it will acquire US biotech firm Terns Pharmaceuticals ...
11d
Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires
Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results